Clinical Trials Browser

Phase 3 × Interventional × tislelizumab × Clear all

Carcinoma, Non-Small-Cell Lung

Advanced Malignancies

Adenocarcinoma Of Esophagus, Parkinson Disease 4, Autosomal Dominant Lewy Body, Esophageal Neoplasms, Stomach Neoplasms

Carcinoma, Non-Small-Cell Lung

Adenocarcinoma

Non Squamous Non-small Cell Lung Cancer

Nasopharyngeal Neoplasms

Carcinoma, Transitional Cell

Stomach Neoplasms

Esophageal Neoplasms

Carcinoma, Non-Small-Cell Lung

B-cell Malignancies

Carcinoma, Non-Small-Cell Lung

Carcinoma, Hepatocellular

Colonic Neoplasms

Esophageal Squamous Cell Carcinoma

Stomach Neoplasms

Gastric Cancer Stage

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Esophageal Squamous Cell Carcinoma

Advanced Squamous Non Small Cell Lung Cancer

Advanced Non-squamous Non-small-cell Lung Cancer

Squamous Cell Carcinoma of Head and Neck

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Nasopharyngeal Neoplasms, Recurrence

Carcinoma, Non-Small-Cell Lung

Colorectal Neoplasms

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma, Neoplasm Metastasis

Nasopharyngeal Carcinoma

Urinary Bladder Neoplasms, Motor Activity, Neoplasm Recurrence, Local

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Nasopharyngeal Carcinoma

Carcinoma, Non-Small-Cell Lung

Clinical Trials

Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

HERIZON-GEA-01

RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)

Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemotherapy for the Treatment of Gastric or Gastroesophageal Junction Adenocarcinoma.

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab Combined With Chemotherapy as First-Line Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer

Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma

Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for Participants With Urothelial Carcinoma

A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab With or Without Pembrolizumab in HER2-high Expression Advanced Gastric or Gastroesophageal Junction Adenocarcinoma.

MRD2START

Phase III Study of SHR-8068 Combined With Adebrelimab and Chemotherapy Versus Tislelizumab Combined With Chemotherapy in the Treatment of Locally Advanced or Metastatic Non-small Cell Lung Cancer

Long-term Extension Study of Zanubrutinib (BGB-3111) Regimens in Participants With B-cell Malignancies

ResQ201A: Clinical Trial Of N-803 Plus TISLELIZUMAB And DOCETAXEL Versus DOCETAXEL Monotherapy In Participants With Advanced Or Metastatic Non-Small Cell Lung Cancer

A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)

Neoadjuvant CAPOX Plus Tislelizumab vs CAPOX in MSS High-Risk Locally Advanced Colon Cancer

A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase III Studyunresectable or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma

Perioperative Tislelizumab Plus Chemotherapy Versus Chemotherapy Alone in MHC-II-Positive Gastric/GEJ Cancer

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

SACTION2401

A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell Carcinoma

AK112 in Combination With Chemotherapy in Advanced Squamous Non-Small Cell Lung Cancer

JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation

Neoadjuvant Immunochemotherapy for LAOSCC

Study of Platinum Plus Etoposide With or Without Tislelizumab in Participants With Untreated Extensive-Stage Small Cell Lung Cancer

RATIONALE-303

A Study Evaluating the Efficacy and Safety of Tislelizumab Versus Chemotherapy in Advanced Non-Squamous Non-small Cell Lung Cancer

RATIONALE-309

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

SMALLER

A Study to Compare Ociperlimab Plus Tislelizumab Versus Durvalumab Following Concurrent Chemoradiotherapy (cCRT) in Participants With Stage III Unresectable Non-Small Cell Lung Cancer

A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma

Tislelizumab in Combination With GP or TPC Regimen for the Treatment of Nasopharyngeal Carcinoma With Bone Metastasis.

Multicenter Clinical Trial on the Effectiveness and Safety of Instillation of BCG and Alternative BCG Protocols for Intermediate and High-risk Non-muscle Invasive Bladder Cancer

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

A Study of AK104/Tislelizumab With Chemotherapy as First-line Treatment in PD-L1 TPS < 1% Non-small Cell Lung Cancer

AdvanTIG-306

Metronomic Capecitabine With or Without PD-1 Antibody as Adjuvant Therapy in High-risk Nasopharyngeal Carcinoma

RATIONALE001